Absorption and disposition of ginsenosides after oral administration of Panax notoginseng extract to rats

Drug Metabolism and Disposition

Volumn 37, Issue 12, 2009, Pages 2290-2298

  Liu, Houfu ^a,b   Yang, Junling ^a   Du, Feifei ^a   Gao, Xiumei ^c   Ma, Xutao ^c   Huang, Yuhong ^c   Xu, Fang ^a   Niu, Wei ^a   Wang, Fengqing ^a   Mao, Yu ^a   Sun, Yan ^a   Lu, Tong ^a   Liu, Changxiao ^d   Zhang, Boli ^c   Li, Chuan ^a,b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GINSENOSIDE; GINSENOSIDE F 1; GINSENOSIDE F 2; GINSENOSIDE RA 3; GINSENOSIDE RB 1; GINSENOSIDE RC; GINSENOSIDE RD; GINSENOSIDE RE; GINSENOSIDE RF; GINSENOSIDE RG 1; GINSENOSIDE RG 2; GINSENOSIDE RG 3; GINSENOSIDE RH 1; GINSENOSIDE RH 2; NOTOGINSENOSIDE R 1; PANAX NOTOGINSENG EXTRACT; SAPONIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; DEGLYCOSYLATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; MALE; MAXIMUM PLASMA CONCENTRATION; MEMBRANE PERMEABILITY; NONHUMAN; PANAX NOTOGINSENG; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION;

ADMINISTRATION, ORAL; ANIMALS; BILE; BIOTRANSFORMATION; CACO-2 CELLS; CARDIOVASCULAR AGENTS; CELL MEMBRANE PERMEABILITY; COLON; DRUGS, CHINESE HERBAL; GINSENOSIDES; GLYCOSYLATION; HUMANS; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; KIDNEY; MALE; MOLECULAR STRUCTURE; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

PANAX NOTOGINSENG; RATTUS;

EID: 71049183577     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.029819     Document Type: Article

References (28)

1. Akao T, Kanaoka M, and Kobashi K (1998) Appearance of compound K, a major metabolite of ginsenoside Rb1 by intestinal bacteria, in rat plasma after oral administration - measurement of compound K by enzyme immunoassay. Biol Pharm Bull 21:245-249. (Pubitemid 28166911)
2. Chinese Pharmacopoeia Commission (2005) Pharmacopoeia of the People's Republic of China, English ed, vol I, pp 10-11, People's Medical Publishing House, Beijing.
3. Cho J, Park W, Lee S, Ahn W, and Lee Y (2004) Ginsenosides-Rb1 from Panax ginseng C.A. Meyer activates estrogen receptor-α and -β, independent of ligand binding. J Clin Endocrinol Metab 89:3510-3515. (Pubitemid 38951928)
4. Dai J-Y, Yang J-L, and Li C (2008) Transport and metabolism of flavonoids from Chinese herbal remedy Xiaochaihu-tang across human intestinal Caco-2 cell monolayers. Acta Pharmacol Sin 29:1086-1093.
5. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
6. 2+ channels in vascular smooth muscle cells. Eur J Pharmacol 548:129-136.
7. Hasegawa H, Sung JH, Matsumiya S, and Uchiyama M (1996) Main ginseng saponin metabolites formed by intestinal bacteria. Planta Med 62:453-457. (Pubitemid 26370341)
8. Kwan CY (1995) Vascular effects of selected antihypertensive drugs derived from traditional medicinal herbs. Clin Exp Pharmacol Physiol 22:s297-s299.
9. 1 acts as a weak phytoestrogen in MCF-7 human breast cancer cells. Arch Pharm Res 26:58-63.
10. Li L, Sheng Y-X, Zhang J-L, Wang C-S, and Guo D-A (2004a) HPLC determination of four active saponins from Panax notoginseng in rat serum and its application to pharmacokinetic studies. Biomed Chromatogr 18:849-856. (Pubitemid 40089858)
11. Li L, Sheng Y-X, Zhang J-L, Wang S-S, and Guo D-A (2006) High-performance liquid chromatographic assay for the active saponins from Panax notoginseng in rat tissues. Biomed Chromatogr 20:327-335.
12. Li X-Y, Sun JG, Wang G-J, Hao H-P, Liang Y, Zheng Y-T, Yan B, and Sheng L-S (2007a) Simultaneous determination of Panax notoginsenoside R1, ginsenoside Rg1, Rd, Re and Rb1 in rat plasma by HPLC/ESI/MS: platform for the pharmacokinetic evaluation of total panax notoginsenoside, a typical kind of multiple constituent traditional Chinese medicine. Biomed Chromatogr 21:735-746. (Pubitemid 47073124)
13. Li X-Y, Wang G-J, Sun J-G, Hao H-P, Xiong Y-Q, Yan B, Zheng Y-T, and Sheng L-S (2007b) Pharmacokinetic and absolute bioavailability study of total Panax notoginseng, a typical multiple constituent traditional Chinese medicine (TCM) in rats. Biol Pharm Bull 30:847-851. (Pubitemid 46708624)
14. Li L, Zhang J-L, Sheng Y-X, Ye G, Guo H-Z, and Guo D-A (2004b) Liquid chromatographic method for determination of four active saponins from Panax notoginseng in rat urine using solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci 808:177-183. (Pubitemid 38952912)
15. Lipinski CA, Lombardo F, Dominy BW, and Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3-26.
16. Liu Z-Q, Luo X-Y, Liu G-Z, Chen Y-P, Wang Z-C, and Sun Y-X (2003) In vitro study of the relationship between the structure of ginsenoside and its antioxidative or prooxidative activity in free radical induced hemolysis of human erythrocytes. J Agric Food Chem 51:2555-2558.
17. Lu T, Yang J-L, Gao X-M, Chen P, Du F-F, Sun Y, Wang F-Q, Xu F, Shang H-C, Huang Y-H, et al. (2008) Plasma and urinary tanshinol from Salvia miltiorrhiza (Danshen), can be used as pharmacokinetic markers for cardiotonic pills, a cardiovascular herbal medicine. Drug Metab Dispos 36:1578-1586.
18. Mashour NH, Lin GI, and Frishman WH (1998) Herbal medicine for the treatment of cardiovascular disease: clinical considerations. Arch Intern Med 158:2225-2234.
19. Ng TB (2006) Pharmacological activity of Sanqi ginseng (Panax notoginseng). J Pharm Pharmacol 58:1007-1019.
20. Odani T, Tanizawa H, and Takino Y (1983a) Studies on the absorption, distribution, excretion and metabolism of ginseng saponins. II. The absorption, distribution and excretion of ginsenoside Rg1 in the rat. Chem Pharm Bull 31:292-298.
21. Odani T, Tanizawa H, and Takino Y (1983b) Studies on the absorption, distribution, excretion and metabolism of ginseng saponins. III. The absorption, distribution and excretion of ginsenoside Rb1 in the rat. Chem Pharm Bull 31:1059-1066.
22. 1 on rat. Anal Biochem 352:87-96.
23. Sengupta S, Toh SA, Sellers LA, Skepper JN, Koolwijk P, Leung HW, Yeung HW, Wong RN, Sasisekharan R, and Fan TP (2004) Modulating angiogenesis: the yin and the yang in ginseng. Circulation 110:1219-1225. (Pubitemid 39202336)
24. Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, and Forgue ST (2000) Confidence interval criteria for assessment of dose proportionality. Pharm Res 17:1278-1283.
25. Tawab MA, Bahr U, Karas M, Wurglics M, and Schubert-Zsilavecz M (2003) Degradation of ginsenosides in humans after oral administration. Drug Metab Dispos 31:1065-1071. (Pubitemid 36975678)
26. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, and Kopple KD (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45:2615-2623.
27. Wang L, Sun Y, Du F-F, Niu W, Lu T, Kan J-M, Xu F, Yuan K-H, Qin T, Liu C-X, et al. (2007) 'LC-electrolyte effects' improve the bioanalytical performance of liquid chromatography/tandem mass spectrometric assays in supporting pharmacokinetic study for drug discovery. Rapid Commun Mass Spectrom 21:2573-2584. (Pubitemid 47255468)
28. Xu Q-F, Fang X-L, and Chen D-F (2003) Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats. J Ethnopharmacol 84:187-192.